samedan logo

 
 
spacer
home > pmps > summer 2017 > nemera – delivering effective devices
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Nemera – Delivering Effective Devices

Nemera always puts patients first, providing the most comprehensive range of devices in the sector, including off-the-shelf innovative systems, customised design development and contract manufacturing. Nemera's services and products cover several key delivery routes:

Ophthalmic

Nemera offers a multidose closing tip system, Novelia®, which avoids the need for preservatives in the drug and prevents bacterial contamination over the duration of treatment.

Novelia® is an innovative, userfriendly, preservative-free multidose eye dropper with a precision blue tip, commercialised for both medical devices and prescription drugs.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.

spacer

Print this page
Send to a friend
Privacy statement
News and Press Releases

Key milestone in molded glass: SGD Pharma elevates Type I offering with three tailored product and service solutions

Puteaux Cedex, FRANCE – 23rd March: SGD Pharma, a leading supplier of glass primary packaging in the pharmaceutical industry and global expert in Type I molded glass, introduces an industry first offering of Type I molded glass vials. These market-driven value propositions represent the latest step in SGD Pharma’s ongoing improvements to its product offers and services. According to their specific business and parenteral drug requirements, Pharma and Biotech players would not only benefit from SGD Pharma’s enhanced high quality and reliable products, but also from an extended offer, ranging from Total Cost of Ownership (TCO) optimization to the highest levels of services.
More info >>

White Papers

Orthogonal Approaches for the Analysis of Protein Sequence and Post Translational Modifications of a Monoclonal Antibody

RSSL

Monoclonal antibodies are an important class of biopharmaceuticals. They are expressed from living cells and therefore, are subject to complex biochemical pathways. Not all of these pathways are fully understood and many are known to be sensitive to subtle environmental changes during production. These changes may affect the final biopharmaceutical sequence, structure and post-translational modifications. This is in addition to any changes that may occur during subsequent purification. This means that the final product from one batch may be subtly different from another batch. Furthermore, each batch is a heterogeneous mix of similar molecules. Analysis of the degree of batch-tobatch variation, and batch heterogeneity, is therefore, very important to establish in order to be confident that the drug is safe and effective for medicinal use.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement